BiotechTube

Sitagliptin-Metformin + Metformin + Placebo pill

ApprovedCompleted
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Disorder of Glucose Regulation

Conditions

Disorder of Glucose Regulation

Trial Timeline

Sep 28, 2013 → Sep 28, 2017

NCT ID
NCT01856907

About Sitagliptin-Metformin + Metformin + Placebo pill

Sitagliptin-Metformin + Metformin + Placebo pill is a approved stage product being developed by Merck for Disorder of Glucose Regulation. The current trial status is completed. This product is registered under clinical trial identifier NCT01856907. Target conditions include Disorder of Glucose Regulation.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT01856907ApprovedCompleted

Competing Products

20 competing products in Disorder of Glucose Regulation

See all competitors
ProductCompanyStageHype Score
Duloxetine + venlafaxine + placeboEli LillyPhase 3
77
Ketamine + PlaceboRoivant SciencesPhase 1
30
duloxetineEli LillyPre-clinical
23
SUBLOCADEIndivior PLCPhase 3
72
SUBLOCADEIndivior PLCPhase 3
72
TSHA-101Taysha Gene TherapiesPhase 1/2
36
OlanzapineEli LillyPhase 3
77
Valproate + Lithium + Risperidone + OlanzapineEli LillyPhase 3
77
Olanzapine + PlaceboEli LillyApproved
85
Duloxetine HydrochlorideEli LillyPre-clinical
23
LY2216684Eli LillyPhase 1
33
ACT-541468 5 mg + ACT-541468 10 mg + ACT-541468 25 mg + Zolpidem + Placebo 1 + Placebo 2IdorsiaPhase 2
47
LY2216684Eli LillyPhase 1
33
atomoxetineEli LillyApproved
85
Atomoxetine + PlaceboEli LillyPhase 2/3
65
LY2422347 + placeboEli LillyPhase 2
52
Low Dose REN001 + High Dose REN001OnKure TherapeuticsPhase 1
25
AtomoxetineEli LillyApproved
85
DuloxetineEli LillyPhase 3
77
Duloxetine (Cymbalta)Eli LillyApproved
85

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85